Riccardo Palmisano, CEO of MolMed, discusses the latest developments for their late-stage clinical development products, and comments on the recent approval of Strimvelis, a gene therapy developed by GSK and MolMed. Can you please give our readers a brief rundown of the history of MolMed since its foundation in 1996? MolMed was founded in 1996 as a joint venture between Boehringer Mannheim and Science Park Raffaele to provide cell therapy services. From 2000 onwards, MolMed evolved into a biopharmaceutical development company, with a primary focus on novel cancer therapies: at the end of 2000, the company entered a new phase, beginning its transformation from service provider into a biopharmaceutical company and thus adopting a business model with greater growth prospects. Pursuant the several in-licensing agreements and out-licensing and co-development agreements signed with different parties since 2001 Molmed enlarged its portfolio with cell therapy and vascular-targeting biopharmacotherapy programs that gave rise to the products currently in late stage clinical trials, TK (Zalmoxis®) and NGR-hTNF, respectively. Quite recently (March 2015) MolMed took a step in immuno-gene therapy acquiring the CAR-CD44v6 project, potentially effective for many hematological malignancies and several epithelial tumors, currently in preclinical development.
Today, MolMed is a mature company covering all functions, from discovery to proof of clinical activity.